You have read all your free articles, to continue reading subscribe to read the rest of this content.
BioArctic’s partner Eisai has announced that under the Accelerated Approval pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.: LEQEMBI) for the treatment of Alzheimer’s disease. The approval concerns lecanemab-irmb (Brand Name in the U.S.:Already a subscriber Login You have read all your…
AlzeCure Pharma has announced the outcome of the rights issue with preferential rights for the shareholders that ended on March 22, 2022. The subscription breakdown show that approximately 59.4 percent was subscribed with and without the exercise of subscription rights. Consequently underwriters Already a subscriber Login You have read all…
Alligator Bioscience has started trading of its shares on the main market of Nasdaq Stockholm. Alligator is a research-based biotechnology company developing antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies and is pAlready a subscriber Login You have read all your free articles, to continue…
Elicera Therapeutics has announced that the subscription period for the company's new share issue prior to the planned listing on Nasdaq First North Growth Market began May 24 and runs until June 8. The new share issue consists of a directed issue of a maximum of 6,500,000 Units, each consisting…
